DBV Technologies S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K, filed on November 3, 2015, reports the interim financial results for DBV Technologies S.A. for the third quarter ended September 30, 2015. DBV is a clinical-stage specialty biopharmaceutical company focused on developing immunotherapy products using its proprietary Viaskin platform, primarily targeting food allergies.
Key Financial Metrics
- Operating Income: Loss of €4.9 million for Q3 2015 (compared to a loss of €3.9 million in Q3 2014).
- Revenue: €107,520 for Q3 2015, derived from sales of the Diallertest Milk diagnostic product.
- Cash and Cash Equivalents: €332.2 million as of September 30, 2015.
- Research Tax Credits: €4.6 million recognized in Q3 2015 (compared to €3.6 million in Q3 2014). An additional €4.3 million in 2014 credits remained unpaid as of September 30, 2015.
- Outstanding Shares: 24,123,249 ordinary shares as of September 30, 2015.
Material Changes vs. Prior Period
- Operating Loss Increase: The operating loss widened by 25.8% year-over-year, primarily driven by an increase in research tax credits recognized in the current period.
- Revenue Decline: Sales of Diallertest Milk decreased to €107,520 from €210,759 in the prior year. Management does not anticipate material future revenue from this product.
- Liquidity Surge: Cash and cash equivalents increased significantly from €104.5 million at June 30, 2015, to €332.2 million at September 30, 2015. This increase followed the closing of an underwritten public offering of 8,280,000 ADSs at $34.00 per ADS on July 20, 2015.
Outlook, Risks, and Management Commentary
Management remains focused on the development of product candidates utilizing the Viaskin platform, including ongoing clinical trials for Viaskin Peanut and Viaskin Milk, and preclinical development for Viaskin Egg. The company is also exploring applications for Eosinophilic Esophagitis and vaccines. The filing includes standard forward-looking statements cautioning that future performance involves substantial risks and uncertainties, including clinical trial outcomes and regulatory approvals. No specific financial guidance was provided in this filing.
Key Facts for Investor Verification
- Verify the status and timeline of the €4.3 million in unpaid 2014 research tax credits.
- Confirm the cash burn rate and runway given the shift away from diagnostic product revenue.
- Review the specific milestones and enrollment status for the Viaskin Peanut and Viaskin Milk clinical trials.
- Monitor the dilution impact of the July 2015 public offering on existing shareholders.